Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Tango Therapeutics, Inc.
Institut Claudius Regaud
Fundación de investigación HM
Myosin Therapeutics Inc.
Northwestern University
National Cancer Institute (NCI)
Tango Therapeutics, Inc.
Mayo Clinic
Beijing Biotech
Case Comprehensive Cancer Center
NaviFUS Corporation
The Methodist Hospital Research Institute
The Methodist Hospital Research Institute
Debiopharm International SA
Starlight Therapeutics Inc.
Jecho Biopharmaceuticals Co., Ltd.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Acerta Pharma BV
Washington University School of Medicine
InSightec
Inovio Pharmaceuticals
National Institutes of Health Clinical Center (CC)
Filamon LTD
Trogenix ltd
Neonc Technologies, Inc.
Eli Lilly and Company
Neonc Technologies, Inc.
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Assistance Publique - Hôpitaux de Paris
Essen Biotech
Essen Biotech
Grupo Español de Investigación en Neurooncología
Genenta Science
Sapience Therapeutics
Cantex Pharmaceuticals
University of California, San Francisco
Institute of Cancer Research, United Kingdom
University of Alabama at Birmingham
Institute of Cancer Research, United Kingdom
InSightec
AHS Cancer Control Alberta
Guangzhou Virotech Pharmaceutical Co., Ltd.
M.D. Anderson Cancer Center
Mianyang Central Hospital
University of Miami
Enterome
Universitair Ziekenhuis Brussel
Turning Point Therapeutics, Inc.